For the latest updates on Gilead’s ongoing response to COVID-19, please click here.

Trials and Expanded Access

Clinical Trials

We are currently investigating multiple disease areas in the axicabtagene ciloleucel and the KTE-X19 development program as well as for our TCR pipeline and second-generation technology. Our areas of research include a variety of blood cancers and solid tumors.

Information on all Kite trials can be found on ClinicalTrials.gov

Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual.

EXPANDED Access

Our expanded-access programs allow for potential access to investigational therapies in certain rare circumstances in which a person has no other available therapies or is not eligible to participate in a current Kite clinical trial. This is part of our commitment to ensuring our medicines are made available to all individuals, regardless of their location or financial situation.

Treating physicians may request information about expanded access for a Kite therapy by contacting Kite medical information at 1-844-454-KITE (5483). Kite will evaluate these requests individually and will acknowledge receipt of the request via telephone call or email within five business days of receipt.